31 / 34
Velour retrospective DNA biomarker analysis:
No significant interaction in
RAS
defined subgroups, although the HR ratios in
RAS
wt
patients appear to be specifically strong
Aflibercept could have an even larger beneficial effect in
BRAF
mut patients
Primary tumor sidedness is prognostic, with right-sided tumors associated with
worse prognosis
Aflibercept appears to result in comparable benefit regardless of primary tumor location
These data provide more granular evidence for treatment options within the
guidelines
Ongoing assessment, including CMS, and discovery of predictive biomarkers will aid decision
making in the future.
Conclusions